Hiv
Conditions
Brief summary
Background: Cytomegalovirus (CMV) infection is usually observed among patients with HIV infection. No study to date has investigated the impact of CMV infection on HIV viral load decay during antiretroviral therapy. Methods: 345 consecutive HIV patients coinfected (N=300) or not (N=45) with CMV were enrolled. Clinical, biological and virological data were collected from HIV antiretroviral therapy initiation to the day of HIV viral load undetectability if any.
Interventions
HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV patients starting an antiretroviral therapy * CMV serology available at antiretroviral therapy initiation * HIV viral load assessed at each follow-up visit after treatment initiation
Exclusion criteria
* HIV antiretroviral treatment initiation before June 2005
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HIV viral load undetectability | From date of HIV therapy initiation until the date of HIV viral load undetectability (12 weeks in average after treatment initiation) | HIV viral load was assessed during the follow-up visits after the initiation of antiretroviral therapy. HIV undetectability was defined by an HIV-RNA level \<50 copies/mL. |
Countries
France
Outcome results
None listed